SCNI:NASDAQ, Scinai Immunotherapeutics Ltd.

Why SCNI stock fell on November 12

Scinai Immunotherapeutics Ltd. fell 13.2% on Thursday, November 12, 2026, on 67,200 shares. No headline about SCNI came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

SCNI stock overview

Scinai Immunotherapeutics Ltd. (SCNI:NASDAQ) closed at $0.404 on November 16, 2026, up 1.03% on the day. The stock trades 96.9% below its 52-week high of $13.00 and 4.4% above its 52-week low of $0.387. Over the past year, it lost 95.8%. Scinai Immunotherapeutics Ltd. is part of the Health Care sector.

Key figures

Price
$0.404
Day change
+1.03%
Volume
27,108
Average volume
2,157,928
Market cap
1M+
52-week range
$0.387 – $13.00
50-day average
$1.09
200-day average
$4.01

Price action over the past year

In 252 trading sessions since November 14, 2025, SCNI closed higher on 100 days (40%). Its best day was April 24, 2026 (+61.62%) and its worst was September 15, 2026 (-36.89%). The stock moved 10% or more in a single session 27 times. It opened at least 5% above the previous day's high 6 times.

Recent signals

SCNI news

About Scinai Immunotherapeutics Ltd.

BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.

Similar stocks

Find more stocks like SCNI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.